基于粪便血红蛋白浓度指导筛查间隔的结直肠癌粪便免疫化学检测精准筛查
该回顾性队列研究利用台湾2004至2014年覆盖350万50至74岁人群的两年一次全国性FIT筛查项目数据,随访至2019年,建立粪便血红蛋白(f-Hb)指导的个体化筛查间隔。结果显示,与全民两年一次筛查相比,f-Hb指导的个体化筛查在等效降低结直肠癌相关结局的前提下,FIT检测次数减少49%、结肠镜检查次数减少28%。
要点
- 基线f-Hb升高与结直肠肿瘤及结直肠癌死亡风险呈持续梯度关系。
- 不同f-Hb水平者被分为不同风险类别并推荐相应筛查间隔。
- 个体化f-Hb指导筛查较全民两年一次筛查减少FIT 49%、结肠镜28%。
核心结论
- f-Hb与结直肠肿瘤及结直肠癌死亡的梯度关系可用于制定f-Hb指导筛查间隔的个体化FIT筛查。
- 该精准筛查间隔在不损害全民两年一次筛查效果的前提下减少了FIT检测和结肠镜的使用。
研究设计与样本
- 回顾性队列研究,利用台湾2004至2014年两年一次全国性FIT筛查项目数据,纳入3 500 250名50至74岁参与者(平均[SD]年龄57.8[6.0]岁),随访至2019年。
- 进一步设计比较研究,在降低结直肠癌相关结局效果等效的前提下,比较个体化f-Hb指导组与全民两年一次筛查组的FIT和结肠镜使用情况。
- 采用泊松回归模型确定一系列f-Hb指导的筛查间隔,数据分析时间为2022年9月至2023年10月。
主要发现
- 基线f-Hb升高与结直肠肿瘤及结直肠癌死亡风险呈持续梯度关系。
- 不同f-Hb水平的参与者被分为不同风险类别,并推荐了不同的筛查间隔。
- 采用所提出的f-Hb指导筛查间隔,个体化方法推算较全民两年一次筛查减少FIT检测次数49%、结肠镜检查次数28%。
关键数值与推荐
- 不同f-Hb水平对应不同风险类别及不同筛查间隔推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Given a gradient relationship between fecal hemoglobin (f-Hb) concentration and colorectal neoplasia demonstrated previously, using f-Hb-guided interscreening interval has increasingly gained attention in population-based fecal immunological test (FIT), but it is very rare to address how to implement such a precision strategy and whether it can economize the use of FIT and colonoscopy. OBJECTIVE: To demonstrate the applicability of personalized colorectal cancer (CRC) screening with f-Hb-guided screening intervals to reduce the number of FITs and colonoscopy with as equivalent efficacy as universal biennial screening. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study for developing f-Hb-guided precision interscreening interval was conducted using data on a Taiwanese biennial nationwide FIT screening program that enrolled more than 3 million participants aged 50 to 74 years between 2004 and 2014. The cohort was followed up over time until 2019 to ascertain colorectal neoplasia and causes of death. A comparative study was further designed to compare the use of FIT and colonoscopy between the personalized f-Hb-guided group and the universal biennial screening group given the equivalent efficacy of reducing CRC-related outcomes. MAIN OUTCOMES AND MEASUREMENTS: A spectrum of f-Hb-guided intervals was determined by using the Poisson regression model given the equivalent efficacy of a universal biennial screening. The use of FIT and colonoscopy for the pragmatic f-Hb-guided interval group was measured compared with the universal biennial screening group. Data analysis was performed from September 2022 to October 2023. RESULTS: Using data from the 3 500 250 participants (mean [SD] age, 57.8 [6.0] years) enrolled in the Taiwanese biennial nationwide FIT screening program, an incremental increase in baseline f-Hb associated with colorectal neoplasia and CRC mortality consistently was observed. Participants with different f-Hb levels were classified into distinct risk categories. Various screening intervals by different f-Hb levels were recommended. Using the proposed f-Hb-guided screening intervals, it was found that the personalized method was imputed to reduce the number of FIT tests and colonoscopies by 49% and 28%, respectively, compared with the universal biennial screening. CONCLUSION AND RELEVANCE: The gradient relationship between f-Hb and colorectal neoplasia and CRC mortality was used to develop personalized FIT screening with f-Hb-guided screening intervals. Such a precision interscreening interval led to the reduced use of FIT test and colonoscopy without compromising the effectiveness of universal biennial screening.
引用
- Yen AM, Hsu CY, Lin TY, et al. Precision Colorectal Cancer Fecal Immunological Test Screening With Fecal-Hemoglobin-Concentration-Guided Interscreening Intervals. JAMA Oncol. 2024. PMID: 38722640. doi:10.1001/jamaoncol.2024.0961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。